Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content
DOI

10.1056/nejmcibr1809628

Type

Journal article

Journal

The New England journal of medicine

Publication Date

10/2018

Volume

379

Pages

1675 - 1677

Addresses

From the Walter and Eliza Hall Institute of Medical Research, the Department of Medical Biology, University of Melbourne, the Department of Diagnostic Haematology, Royal Melbourne Hospital, and Clinical Haematology at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital - all in Parkville, VIC, Australia (S.-R.P.); and the Weatherall Institute of Molecular Medicine, Medical Research Council Human Immunology Unit, and Haematology Theme, Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom (H.D.).

Keywords

Erythroid Cells, Humans, Anemia, Sickle Cell, eIF-2 Kinase, Fetal Hemoglobin, Carrier Proteins, Gene Expression Regulation, Molecular Targeted Therapy, CRISPR-Cas Systems